Cohance Lifesciences Limited

COHANCENotably above fair value

A 6-pillar fundamental profile. Each pillar scored 0–10.

4.9/10 composite
Prism for COHANCE.NS: composite 4.9 of 10, verdict Notably above fair valuePULSEQUALITYMOATSAFETYGROWTHVALUEn/a0.00.00.00.00.0

Pulse

— · Neutral

Pulse data unavailable; neutral placeholder

Pulse tracks recent momentum in price, analyst revisions, and news sentiment. Higher means stronger near-term tailwinds.

Quality

5.1 · Moderate

Piotroski 5/9, ROCE 13.3%

Quality captures profitability, return on capital, and earnings consistency. Higher means a better business.

Moat

6.5 · Moderate

Narrow moat

Moat estimates durable competitive advantages — brand, scale, switching costs. Higher means more defensible.

Safety

7.0 · Moderate

Int cov 31.0x

Safety looks at balance-sheet strength, leverage, and cash generation. Higher means lower financial risk.

Growth

6.5 · Moderate

Rev CAGR 14.9%

Growth reflects revenue and earnings expansion over recent years. Higher means faster compounding.

Value

0.1 · Weak

MoS -57%

Value measures whether the stock is cheap relative to its intrinsic worth. Higher is cheaper.

Compare with another stock

Overlay COHANCE's prism against a peer.

Share this prism

Share on XWhatsApp

Get the full analysis

Interactive DCF, sensitivity, peer comparison, and AI summary for COHANCE.

Full analysis →

Model estimate. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.